<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00787137</url>
  </required_header>
  <id_info>
    <org_study_id>PG102-01</org_study_id>
    <secondary_id>2007-001017-42</secondary_id>
    <nct_id>NCT00787137</nct_id>
  </id_info>
  <brief_title>Single Dose PG102 in Patients With Active Psoriatic Arthritis</brief_title>
  <official_title>A Randomised, Double Blind, Placebo Controlled, Single Ascending Dose, Phase I Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of PG102 (Anti-CD40 Monoclonal Antibody) In Patients With Active Psoriatic Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PanGenetics UK Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PanGenetics UK Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to evaluate the safety and tolerability of a single intravenous dose
      of PG102 in patients with psoriatic arthritis. The secondary objectives are to evaluate how
      PG102 moves around the body and to explore its effects on the disease.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    poor recruitment
  </why_stopped>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Number of Reported Adverse Events</measure>
    <time_frame>Three months</time_frame>
    <description>This was an exploratory study and all safety endpoints were considered.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Percentage of Participants With Adverse Events</measure>
    <time_frame>Three months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The Number of Episodes of Change in Vital Signs</measure>
    <time_frame>Three months</time_frame>
    <description>Clinically significant episodes of change in blood pressure, heart rate, temperature or respiration rate on the day before dosing and 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours and 4, 7, 14, 21, 28, 56 &amp; 84 days after dosing. The investigator evaluated clinical significance primarily by blinded comparison with the respective screening value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Number of Episodes of Change in Electrocardiogram</measure>
    <time_frame>Three months</time_frame>
    <description>Episodes of clinically significant change in 12-lead electrocardiogram predose,1 &amp; 4 hours and 1 &amp; 84 days postdose. The investigator evaluated clinical significance primarily by blinded comparison with the screening electrocardiogram.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Number of Episodes of Change From Screening in Laboratory Assessments</measure>
    <time_frame>Three months</time_frame>
    <description>Red cell count, haemoglobin, haematocrit, total and differential white cell counts, platelet count, mean corpuscular volume, mean corpuscular haemoglobin, mean corpuscular haemoglobin concentration, reticulocytes; urea, creatinine, urate, bilirubin, sodium, potassium, calcium, phosphate, chloride, bicarbonate, alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase, gammaglutamyl transferase, creatine phosphokinase, albumin, protein; urine pH, protein, glucose, ketones, bilirubin, blood, urobilinogen, nitrite, leucocytes, specific gravity.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Arthritis, Psoriatic</condition>
  <arm_group>
    <arm_group_label>PG102 0.3 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lowest dose PG102</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PG102 1 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Second dose PG102</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (phosphate-buffered saline)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PG102</intervention_name>
    <description>A single intravenous infusion</description>
    <arm_group_label>PG102 0.3 mg/kg</arm_group_label>
    <arm_group_label>PG102 1 mg/kg</arm_group_label>
    <other_name>Anti-CD40 monoclonal antibody</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo comparator</intervention_name>
    <description>Phosphate-buffered saline</description>
    <arm_group_label>Placebo (phosphate-buffered saline)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Arthritis that meets Classification of Psoriatic Arthritis (CASPAR) criteria

          -  Plaque psoriasis for at least 6 months prior to study enrollment

        Exclusion Criteria:

          -  Clinically significant psoriasis flare

          -  Unstable doses of pain relief medication

          -  Treatment with systemic corticosteroids other than prednisone ≤ 10 mg/day or
             equivalent

          -  Treatment with any biologic therapy

          -  Treatment with immunosuppressive agents or disease modifying anti-rheumatic drugs
             (DMARDs) other than methotrexate

          -  Treatment with lithium, any anti-malarial, chlorambucil, cyclophosphamide or therapies
             for psoriasis other than low potency topical corticosteroids on intertriginous and
             groin areas, tar or salicylate preparations on the scalp, and emollients and
             moisturisers

          -  Family history of multiple thrombotic events or a personal history of any venous or
             arterial thrombotic event

          -  Clinically significant result for anti-cardiolipin, Activated protein C resistance
             test, Protein C, Free Protein S, Antithrombin III, Factor V Leiden, Prothrombin
             variant, Homocysteine, Lupus anticoagulant, Prothrombin time, Activated partial
             thromboplastin time, Fibrinogen, Thrombin time, Factors IX and XI

          -  Currently smoking ≥ 10 cigarettes per day or equivalent

          -  Active tuberculosis or other infection

          -  Current or previous malignancies

          -  Clinically significant abnormality on physical examination, laboratory testing, vital
             signs or 12-lead electrocardiogram
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nemanja Damjanov, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Rheumatology, Belgrade, Serbia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Professor Nemanja Damjanov</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Serbia</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 6, 2008</study_first_submitted>
  <study_first_submitted_qc>November 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2008</study_first_posted>
  <results_first_submitted>August 12, 2010</results_first_submitted>
  <results_first_submitted_qc>September 25, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 15, 2010</results_first_posted>
  <last_update_submitted>October 15, 2010</last_update_submitted>
  <last_update_submitted_qc>October 15, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2010</last_update_posted>
  <responsible_party>
    <name_title>John Powell</name_title>
    <organization>PanGenetics UK Limited</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Eight study sites (rheumatology centres) in Serbia (3), Hungary (4) and the Russian Federation (1). The first patient's first visit was on December 2, 2008 and the last visit for the last patient was on April 21, 2010.</recruitment_details>
      <pre_assignment_details>The first three patients in each cohort were dosed sequentially and could not be taking methotrexate. Subsequent patients in each cohort could be dosed simultaneously and could be taking methotrexate. There was a pause between dosing the last patient in the first cohort and the first patient in the second cohort.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>PG102 0.3 mg/kg</title>
          <description>Lowest dose PG102</description>
        </group>
        <group group_id="P2">
          <title>PG102 1 mg/kg</title>
          <description>Second dose PG102</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Control, phosphate-buffered saline</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study Termination</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PG102 0.3 mg/kg</title>
          <description>Lowest dose PG102</description>
        </group>
        <group group_id="B2">
          <title>PG102 1 mg/kg</title>
          <description>Second dose PG102</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Control, phosphate-buffered saline</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="5"/>
            <count group_id="B4" value="17"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.3" spread="9.77" lower_limit="32" upper_limit="54"/>
                    <measurement group_id="B2" value="43.8" spread="10.85" lower_limit="27" upper_limit="59"/>
                    <measurement group_id="B3" value="45.2" spread="13.20" lower_limit="31" upper_limit="58"/>
                    <measurement group_id="B4" value="44.0" lower_limit="27" upper_limit="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Serbia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Number of Reported Adverse Events</title>
        <description>This was an exploratory study and all safety endpoints were considered.</description>
        <time_frame>Three months</time_frame>
        <population>All adverse events reported for all patients dosed were evaluated</population>
        <group_list>
          <group group_id="O1">
            <title>PG102 0.3 mg/kg</title>
            <description>Lowest dose PG102</description>
          </group>
          <group group_id="O2">
            <title>PG102 1 mg/kg</title>
            <description>Second dose PG102</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Control, phosphate-buffered saline</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Reported Adverse Events</title>
          <description>This was an exploratory study and all safety endpoints were considered.</description>
          <population>All adverse events reported for all patients dosed were evaluated</population>
          <units>Number of adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Percentage of Participants With Adverse Events</title>
        <time_frame>Three months</time_frame>
        <population>All patients dosed were evaluated</population>
        <group_list>
          <group group_id="O1">
            <title>PG102 0.3 mg/kg</title>
            <description>Lowest dose PG102</description>
          </group>
          <group group_id="O2">
            <title>PG102 1 mg/kg</title>
            <description>Second dose PG102</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Control, phosphate-buffered saline</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Participants With Adverse Events</title>
          <population>All patients dosed were evaluated</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="67"/>
                    <measurement group_id="O3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Number of Episodes of Change in Vital Signs</title>
        <description>Clinically significant episodes of change in blood pressure, heart rate, temperature or respiration rate on the day before dosing and 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours and 4, 7, 14, 21, 28, 56 &amp; 84 days after dosing. The investigator evaluated clinical significance primarily by blinded comparison with the respective screening value.</description>
        <time_frame>Three months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PG102 0.3 mg/kg</title>
            <description>Lowest dose PG102</description>
          </group>
          <group group_id="O2">
            <title>PG102 1 mg/kg</title>
            <description>Second dose PG102</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Control, phosphate-buffered saline</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Episodes of Change in Vital Signs</title>
          <description>Clinically significant episodes of change in blood pressure, heart rate, temperature or respiration rate on the day before dosing and 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours and 4, 7, 14, 21, 28, 56 &amp; 84 days after dosing. The investigator evaluated clinical significance primarily by blinded comparison with the respective screening value.</description>
          <units>Number of episodes of change</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Number of Episodes of Change in Electrocardiogram</title>
        <description>Episodes of clinically significant change in 12-lead electrocardiogram predose,1 &amp; 4 hours and 1 &amp; 84 days postdose. The investigator evaluated clinical significance primarily by blinded comparison with the screening electrocardiogram.</description>
        <time_frame>Three months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PG102 0.3 mg/kg</title>
            <description>Lowest dose PG102</description>
          </group>
          <group group_id="O2">
            <title>PG102 1 mg/kg</title>
            <description>Second dose PG102</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Control, phosphate-buffered saline</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Episodes of Change in Electrocardiogram</title>
          <description>Episodes of clinically significant change in 12-lead electrocardiogram predose,1 &amp; 4 hours and 1 &amp; 84 days postdose. The investigator evaluated clinical significance primarily by blinded comparison with the screening electrocardiogram.</description>
          <units>Number of episodes of change</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Number of Episodes of Change From Screening in Laboratory Assessments</title>
        <description>Red cell count, haemoglobin, haematocrit, total and differential white cell counts, platelet count, mean corpuscular volume, mean corpuscular haemoglobin, mean corpuscular haemoglobin concentration, reticulocytes; urea, creatinine, urate, bilirubin, sodium, potassium, calcium, phosphate, chloride, bicarbonate, alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase, gammaglutamyl transferase, creatine phosphokinase, albumin, protein; urine pH, protein, glucose, ketones, bilirubin, blood, urobilinogen, nitrite, leucocytes, specific gravity.</description>
        <time_frame>Three months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PG102 0.3 mg/kg</title>
            <description>Lowest dose PG102</description>
          </group>
          <group group_id="O2">
            <title>PG102 1 mg/kg</title>
            <description>Second dose PG102</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Control, phosphate-buffered saline</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Episodes of Change From Screening in Laboratory Assessments</title>
          <description>Red cell count, haemoglobin, haematocrit, total and differential white cell counts, platelet count, mean corpuscular volume, mean corpuscular haemoglobin, mean corpuscular haemoglobin concentration, reticulocytes; urea, creatinine, urate, bilirubin, sodium, potassium, calcium, phosphate, chloride, bicarbonate, alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase, gammaglutamyl transferase, creatine phosphokinase, albumin, protein; urine pH, protein, glucose, ketones, bilirubin, blood, urobilinogen, nitrite, leucocytes, specific gravity.</description>
          <units>Number of episodes of change</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>PG102 0.3 mg/kg</title>
          <description>Lowest dose PG102</description>
        </group>
        <group group_id="E2">
          <title>PG102 1 mg/kg</title>
          <description>Second dose PG102</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Control, phosphate-buffered saline</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leucocytosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Transaminases increased/hepatic enzymes increased</sub_title>
                <description>The term for transaminases increased and hepatic enzymes increased have been grouped together because the events were comparable in ALT/AST ratio, involvement or lack of involvement of other analytes and in time of onset.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Neutrophil count increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="6" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>An investigator shall not publish any data (poster, abstract, paper etc) without having consulted with the Sponsor in advance.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Termination prior to accrual of planned numbers of participants</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>John Powell</name_or_title>
      <organization>PanGenetics UK Limited</organization>
      <phone>+441763257869</phone>
      <email>info@pangenetics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

